Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...

November 25, 2024 Biohaven's spinal muscular atrophy drug fails to meet study goal Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly ...

Biohaven Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases. The compounds are oral ...

Biohaven Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates that target neurological and psychiatric diseases.